Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 18/20 | 0.47 |
| ▸ | NOS1 | P29475 | 17/20 | 0.47 |
| ▸ | NOS3 | P29474 | 13/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30774788 | 0.82 | ALDH1A1 (0.43) | NOS2NOS1NOS3MEN1ALDH1A1 | |
| SCHEMBL30774893 | 0.80 | NOS2 (0.38) | NOS2NOS1NOS3L3MBTL1MEN1 | |
| SCHEMBL30774766 | 0.79 | ALDH1A1 (0.53) | L3MBTL1MEN1ALDH1A1LMNAGAA | |
| SCHEMBL30774828 | 0.78 | NOS2 (0.36) | NOS2NOS1NOS3L3MBTL1MEN1 | |
| SCHEMBL31448747 | 0.78 | NOS3 (0.39) | NOS2NOS1NOS3MEN1ALDH1A1 | |
| SCHEMBL30774813 | 0.78 | NOS2 (0.40) | NOS2NOS1NOS3L3MBTL1MEN1 | |
| SCHEMBL30774808 | 0.78 | LMNA (0.44) | L3MBTL1MEN1ALDH1A1LMNAGAA | |
| SCHEMBL30774815 | 0.76 | ALDH1A1 (0.42) | NOS2NOS1NOS3ALDH1A1LMNA | |
| SCHEMBL30774675 | 0.76 | HRH3 (0.34) | NOS2NOS1NOS3MEN1ALDH1A1 | |
| SCHEMBL31448722 | 0.75 | HRH3 (0.37) | NOS2NOS1NOS3MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049068-A1 | Substituted Tetrazolyl Compounds Useful as T Cell Activators | BRISTOL MYERS SQUIBB CO (US) | 2026-02-19 | — | — | US | claimed |
| CN-119654312-A | Substituted tetrazolyl compounds useful as T cell activators | 百时美施贵宝公司 | 2025-03-18 | — | — | CN | claimed |
| US-20260049068-A1 | Substituted Tetrazolyl Compounds Useful as T Cell Activators | BRISTOL MYERS SQUIBB CO (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4568950-A1 | SUBSTITUTED TETRAZOLYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119654312-A | Substituted tetrazolyl compounds useful as T cell activators | 百时美施贵宝公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024036100-A1 | SUBSTITUTED TETRAZOLYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049068-A1 | Substituted Tetrazolyl Compounds Useful as T Cell Activators | DGKZ, DGKA, DGKG | NOS2 3835/4885NOS1 3288/4885NOS3 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.